Management of blood loss in children of Jehovah's Witnesses

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7027.380c (Published 10 February 1996) Cite this as: BMJ 1996;312:380
  1. James A Morecrofta,
  2. Rob A Wheelera,
  3. David P Drakea,
  4. Vanessa M Wrighta
  1. Senior registrar in paediatric surgery Sheffield Children's Hospital, Sheffield S10 2TH j.a.morecroft@sheffield.ac.uk
  2. Consultant paediatric surgeon Southampton General Hospital, Southampton SO9 4XY
  3. Consultant paediatric surgeon Great Ormond Street Hospital for Sick Children, London WC1N 3JH
  4. Consultant paediatric surgeon Queen Elizabeth Hospital for Children, London E2 8PS

    EDITOR,—David Busuttil and Adrian Copplestone's editorial on the management of blood loss in Jehovah's Witnesses touches on, but does not resolve, the clinical and ethical issues of treating children of Jehovah's Witnesses.1 The authors concentrate on the use of recombinant erythropoietin in the postoperative management of anaemia at the expense of considering other pharmacological agents, such as aprotinin or desmopressin, which can reduce intraoperative blood loss. As paediatric surgeons we are aware of the need …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription